Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults—Ineffectiveness of Oral Anticoagulation Treatment with VKA

Table 1

Subjects’ baseline data and cardiovascular risk factors in AF patients and the average CHA₂DS₂VAS_C and HAS-BLED scores.

Subjects
Registered AF prevalence	( 3638)
	(7.5%; CI = 95%, 7.29–7.76)
Women (%)	1688 (46.4)
Mean age (years)	78.7 ± 7.30
Age ≥75 y (%)	74.5
Hypertension (% CI = 95%)	77.1 (CI = 95%, 71.9–82.3)
Diabetes mellitus (% CI = 95%)	26.5 (CI = 95%, 21.1–32.01)
Vascular disease (% CI = 95%)	14.7 (CI = 95%, 10.35–19.16)
Previous stroke/TIA (% CI = 95%)	17.4 (CI = 95%, 12.65–22.03)
Heart failure (% CI = 95%)	22.8 (CI = 95%, 17.7–20.06)
Thromboembolism (% CI = 95%)	2.2 (CI = 95%, 0.27–4.15)
CHA2DS2VASC score ≥2; (% CI = 95%)	95.6 (CI = 95%, 92.9–98.2)
HAS-BLED score ≥3 (% CI = 95%)	47.6 (CI = 95%, 45.7–49.4)
TTR ≥ 60 (%)	67.0 (CI = 95%, 65.2–68.8)
Vitamin K antagonism (VKA) therapy (% CI = 95%)	68.9% (CI = 95%, 67.3–70.4)